Bridges Investment Counsel Inc. raised its stake in Allergan PLC. (NYSE:AGN) by 102.4% during the second quarter, Holdings Channel reports. The fund owned 21,908 shares of the company’s stock after buying an additional 11,086 shares during the period. Allergan PLC. comprises 1.2% of Bridges Investment Counsel Inc.’s portfolio, making the stock its 29th largest position. Bridges Investment Counsel Inc.’s holdings in Allergan PLC. were worth $5,326,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of AGN. Manning & Napier Advisors LLC boosted its stake in Allergan PLC. by 21.3% in the first quarter. Manning & Napier Advisors LLC now owns 11,980 shares of the company’s stock valued at $2,862,000 after buying an additional 2,100 shares during the last quarter. Trust Co boosted its stake in Allergan PLC. by 0.7% in the fourth quarter. Trust Co now owns 1,214 shares of the company’s stock valued at $255,000 after buying an additional 9 shares during the last quarter. Raymond James Trust N.A. boosted its stake in Allergan PLC. by 7.6% in the first quarter. Raymond James Trust N.A. now owns 8,868 shares of the company’s stock valued at $2,119,000 after buying an additional 629 shares during the last quarter. Charter Trust Co. acquired a new stake in Allergan PLC. during the first quarter valued at about $213,000. Finally, Douglass Winthrop Advisors LLC boosted its stake in Allergan PLC. by 15.6% in the first quarter. Douglass Winthrop Advisors LLC now owns 11,675 shares of the company’s stock valued at $2,789,000 after buying an additional 1,574 shares during the last quarter. 84.77% of the stock is currently owned by institutional investors.

Shares of Allergan PLC. (AGN) traded down 0.385% during trading on Monday, reaching $241.715. 824,072 shares of the company were exchanged. The firm has a market capitalization of $81.18 billion, a PE ratio of 7.531 and a beta of 1.16. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company’s 50-day moving average is $245.21 and its 200 day moving average is $237.12.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period last year, the firm earned $3.35 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.20 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.15%. Allergan PLC.’s dividend payout ratio is presently 9.95%.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/allergan-plc-agn-stake-increased-by-bridges-investment-counsel-inc.html.

Several analysts recently issued reports on AGN shares. Royal Bank Of Canada set a $279.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research note on Wednesday, April 12th. Citigroup Inc. reissued a “focus list” rating and issued a $261.27 target price (up from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research report on Wednesday, May 10th. UBS AG reaffirmed a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $274.14.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.36% of the stock is currently owned by company insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.